NCT03162627 2026-04-15Selumetinib and Olaparib in Solid TumorsM.D. Anderson Cancer CenterPhase 1 Active not recruiting90 enrolled
NCT00600496 2025-11-13A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZenecaPhase 1 Active not recruiting140 enrolled